NSE - Free Realtime Quote INR

Glenmark Pharmaceuticals Limited (GLENMARK.NS)

Compare
1,695.55 -21.25 (-1.24%)
As of 1:51 PM GMT+5:30. Market Open.
Currency in INR All numbers in thousands
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
3/31/2020
Total Revenue
118,602,860.00
116,354,560.00
114,319,380.00
121,741,980.00
108,060,260.00
--
Cost of Revenue
43,356,550.00
44,133,700.00
42,575,360.00
47,781,710.00
39,966,250.00
--
Gross Profit
75,246,310.00
72,220,860.00
71,744,020.00
73,960,270.00
68,094,010.00
--
Operating Expense
67,360,940.00
66,086,610.00
61,085,710.00
55,559,790.00
50,933,650.00
--
Operating Income
7,885,370.00
6,134,250.00
10,658,310.00
18,400,480.00
17,160,360.00
--
Net Non Operating Interest Income Expense
-4,439,430.00
-5,159,690.00
-3,490,360.00
-2,886,640.00
-3,504,660.00
--
Pretax Income
3,474,260.00
364,950.00
2,398,420.00
14,412,460.00
13,824,750.00
--
Tax Provision
18,757,160.00
18,673,450.00
3,294,030.00
4,475,970.00
4,123,870.00
--
Net Income Common Stockholders
-13,113,320.00
-15,016,680.00
2,972,450.00
9,417,110.00
9,700,380.00
--
Diluted NI Available to Com Stockholders
-13,113,320.00
-15,016,680.00
2,972,450.00
9,417,110.00
9,700,380.00
--
Basic EPS
-46.47
-53.22
10.53
33.37
34.38
--
Diluted EPS
-46.47
-53.22
10.53
33.37
34.38
--
Basic Average Shares
282,109.64
282,162.35
282,283.95
282,168.16
282,168.16
--
Diluted Average Shares
282,109.64
282,162.35
282,283.95
282,168.16
282,168.16
--
Rent Expense Supplemental
--
--
560,240.00
353,540.00
378,990.00
381,240.00
Total Expenses
110,717,490.00
110,220,310.00
103,661,070.00
103,341,500.00
90,899,900.00
--
Net Income from Continuing & Discontinued Operation
-13,113,320.00
-15,016,680.00
2,972,450.00
9,417,110.00
9,700,380.00
--
Normalized Income
-9,789,576.00
-12,683,275.00
3,663,818.00
11,260,507.23
9,385,322.00
--
Interest Income
--
--
227,660.00
94,350.00
26,470.00
46,760.00
Interest Expense
4,439,430.00
5,159,690.00
3,490,360.00
2,980,990.00
3,531,130.00
--
Net Interest Income
-4,439,430.00
-5,159,690.00
-3,490,360.00
-2,886,640.00
-3,504,660.00
--
EBIT
7,913,690.00
5,524,640.00
5,888,780.00
17,393,450.00
17,355,880.00
--
EBITDA
13,490,240.00
11,832,740.00
12,001,460.00
22,260,600.00
21,791,420.00
--
Reconciled Cost of Revenue
43,356,550.00
44,133,700.00
42,575,360.00
47,781,710.00
39,966,250.00
--
Reconciled Depreciation
5,576,550.00
6,308,100.00
6,112,680.00
4,867,150.00
4,435,540.00
--
Net Income from Continuing Operation Net Minority Interest
-15,732,100.00
-18,989,960.00
-1,697,160.00
9,417,110.00
9,700,380.00
--
Total Unusual Items Excluding Goodwill
-8,489,320.00
-9,009,550.00
-7,658,540.00
-2,673,770.00
448,990.00
--
Total Unusual Items
-8,489,320.00
-9,009,550.00
-7,658,540.00
-2,673,770.00
448,990.00
--
Normalized EBITDA
21,979,560.00
20,842,290.00
19,660,000.00
24,934,370.00
21,342,430.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-2,546,796.00
-2,702,865.00
-2,297,562.00
-830,372.77
133,932.00
--
3/31/2020 - 7/1/2002

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers